This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

LivaNova PLC
11/4/2026
Good day, ladies and gentlemen, and welcome to the LevaNova PLC third quarter 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. As a reminder, this conference call is being recorded. I would now like to introduce you to our host for today's conference, Ms. Briana Gotlin, LevaNova's vice president of investor relations. Briana, please go ahead.
Thank you and welcome to our conference call and webcast discussing LevaNova's financial results for the third quarter of 2026. Joining me on today's call are Vladimir Makatsaria, our Chief Executive Officer and member of the Board of Directors, Alex Shvartsburg, our Chief Financial Officer, and Ahmet Tezel, our Chief Innovation Officer. Before we begin, I would like to remind you that discussions during this call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings and documents furnished to the SEC, including today's press release that is available on our website. We do not undertake to update any forward-looking statement. Also, the discussions will include certain non-GAAP financial measures with respect to performance, including but not limited to revenue results, which will be stated on a constant currency basis. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is available on our website. We have also posted a presentation to our website that summarizes the points of today's calls. This presentation is complementary to the other call materials and should be used as an enhanced communication tool. You can find the presentation and the press release in the investor section of our website under news, events, and presentations at investor.Levanova.com. With that, I'll turn the call over to Vlad.
Thank you, Briana, and thank you everyone for joining us today. Welcome to Levanova's conference call for the third quarter of 2026. Livanova delivered another quarter of double-digit revenue growth with strength across all regions, driven by commercial execution and healthy demand for our cardiopulmonary and epilepsy technologies. The core businesses continue to fuel both current performance and discipline investment, enabling us to further strengthen our existing franchises while advancing new growth opportunities such as obstructive sleep apnea or OSA. As we prepare to enter this attractive, high-growth, high-margin market, our team is focused on building a strong foundation for long-term success in OSA. Importantly, we're not building from the ground up. We're leveraging our neuromodulation capabilities developed through our epilepsy business, including product development expertise, established supply chain infrastructure, a global footprint, and market access competencies. To complement this existing strengths, we have also made key hires across the OSA commercial leadership team, adding targeted expertise as we prepare for commercialization. The strength of LevaNova's capabilities supports future market access for proximal hypoglossal nerve stimulation or PHGNS. Recently, LevaNova contributed its robust clinical evidence to the CPT code application reviewed by the AMA editorial panel. Our Osprey randomized control trial provided level one evidence to support this application. We're pleased with the decision to establish new category one codes that will include LevaNova's technology. Subject to finalization, the new codes are expected to take effect on January 1st, 2028. We believe this decision is an important development that further bolsters our ability to achieve appropriate reimbursement. We're proud to have supported efforts to improve patient access to care and look forward to leveraging this new category codes once effective in the commercialization of our OSA technology. With PAGNS, we believe we have a clear right to win supported by rigorous clinical evidence, a differentiated technology designed for a broader and more complex patient population and leading neuromodulation capabilities across liver nodes. For the remainder of the call, I will discuss the third quarter results and provide updated top line guidance for 2026. After my comments, Ahmet will discuss key innovation updates and Alex will then provide additional details on our results and updated 2026 guidance. I will wrap up with closing remarks before moving on to Q&A. Now turning to segment results. For the cardiopulmonary segment, revenue was $225 million in the quarter, an increase of 11% versus the third quarter of 2025, led by double-digit growth in both Europe and the US. Heart-lung machine revenue grew low double digits in the quarter, marked by quarterly record essence placements and sustained favorable price premiums. Cardiopulmonary consumables revenue, which encompasses all non-HLM products in our cardiopulmonary portfolio, grew low double digits in the quarter. This was led by strength in oxygenators and perfusion tubing kits. Improvements in third-party component availability and internal manufacturing optimization drove significant year-over-year increases in oxygenator output. supporting strong performance year-to-date. Oxygenator market demand continues to exceed the industry's ability to supply, which represents a significant opportunity to expand our market position. As a reminder, our three key operational initiatives to capture this opportunity are optimizing processes across our supply chain network, The operational launch of the new dedicated oxygenator manufacturing line marks another key milestone in the execution of our strategy. Together with the Thermo Fisher component agreement announced last quarter represents significant progress across this three and positions us to drive double digit capacity expansion in 2027. Strong performance across our leading product lines combined with healthy underlying global demand and operational execution reinforces our confidence in the durability of growth in the cardiopulmonary business. As the market leader in HLM with a global installed base of more than 10,000 systems, and Essence representing only about 20% of that base today, we see a significant multi-year upgrade opportunity ahead. For the full year 2026, we now expect cardiopulmonary revenue to grow 10.5% to 11.5% up from 9.5% to 10.5% previously. We continue to expect Essence to represent approximately 80% of annual HLM units placements in 2026, up from 55% in 2025. This forecast also assumes continued market share gains in consumables as we execute on our manufacturing expansion plans. Turning to epilepsy, revenue increased 11% versus the third quarter of 2025 with double digit growth across all regions. U.S. epilepsy revenue increased 10% versus the prior year period, while epilepsy revenue in the Europe and rest of world regions increased a combined 14% year over year. Performance was driven by volume and favorable realized price. supported by impactful clinical evidence, improved reimbursement, and sustained commercial excellence. Similar to the prior quarter, improved realized price in the third quarter benefited from reduced volume discounting, in addition to our standard annual list price increase. The long-term clinical evidence from our core VNS study is strengthening physician confidence, accelerating referrals, and will support earlier adoption of VNS therapy in the patient care pathway. At the same time, improved US reimbursement is translating into stronger provider economics and broader access, driving higher procedure volumes. As a result, we're raising full year 2026 epilepsy revenue growth outlook to 8-9%, up from 7-8% previously. In summary, our third quarter performance reflects the strength of growth drivers across our portfolio, including the ongoing essence upgrade cycle and continued oxygenator market share gains in cardiopulmonary, as well as favorable U.S. reimbursement dynamics and growing clinical evidence supporting VNS therapy in epilepsy. We expect the strands to continue supporting sustainable growth while positioning us to advance our OSA strategy. As a result, we are now guiding full year 2026 revenue growth between 9% to 10%, up from 8% to 9% previously. Alex will provide additional details on our 2026 guidance later in the call. With that, I'll hand the call over to Ahmet to cover key innovation updates across the portfolio.
You're reading a preview of the LIVN Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing